FLT3-ITD/FLT3 D835, F691/NPM1
| Purpose: | Mutations in FLT3 and NPM1 are commonly seen in acute myeloid leukemia. The presence of FLT3 mutations may predict sensitivity or resistance to targeted therapies, and the presence of FLT3/NPM1 mutations are associated with prognosis. Commonly seen FLT3 internal tandem duplications (FLT3-ITD) in the juxtamembrane domain and NPM1 mutations in exon 12 (most commonly a 4 base pair insertion/duplication) are detected by PCR and capillary electrophoresis. Missense F691 and D835 mutations in exon 17 and exon 20 of FLT3 are detected by PCR and direct dideoxyterminator DNA sequencing. |
| CPT Codes: | 81245, 81246, 81310 |
| Methodology: | PCR and capillary electrophoresis and PCR-Sanger sequencing of DNA obtained from blood, bone marrow, or cell suspensions. At least 30% or greater lesional cells are required for detection. This test should not be ordered for MRD evaluation. |
| Turnaround Time: | 5 days |
| Sample Tested: | Blood, bone marrow, cell suspensions and/or extracted DNA. |
| Forms: | 1. PGM Oncology Requisition 2. Medicare Advance Beneficiary Notice |